Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Receivables (2022 - 2025)

Axsome Therapeutics' Change in Receivables history spans 4 years, with the latest figure at $28.0 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 56.14% year-over-year to $28.0 million; the TTM value through Dec 2025 reached $82.5 million, up 74.78%, while the annual FY2025 figure was $82.5 million, 74.78% up from the prior year.
  • Change in Receivables for Q4 2025 was $28.0 million at Axsome Therapeutics, up from -$2.3 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $37.4 million in Q2 2025 and bottomed at -$2.3 million in Q3 2025.
  • The 4-year median for Change in Receivables is $16.9 million (2022), against an average of $14.9 million.
  • The largest YoY upside for Change in Receivables was 193.21% in 2025 against a maximum downside of 161.75% in 2025.
  • A 4-year view of Change in Receivables shows it stood at $17.4 million in 2022, then decreased by 5.7% to $16.4 million in 2023, then increased by 9.14% to $17.9 million in 2024, then surged by 56.14% to $28.0 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Change in Receivables are $28.0 million (Q4 2025), -$2.3 million (Q3 2025), and $37.4 million (Q2 2025).